AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019
Feb 20, 2019
31580_dirs_2019-02-20_683a1350-e601-4381-adfc-f23fb832e7e6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-02-16
Reporting Person: Biller Scott (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-02-16 | Common stock | M | 2750 | — | Acquired | 27387 | Direct |
| 2019-02-19 | Common stock | F | 876 | $58.03 | Disposed | 26511 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-02-16 | Restricted stock units | $ | M | 2750 | Disposed | Common stock (2750) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 53059 | Indirect |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
F3: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.